Why Rare Disease Clinical Trials Take Too Long and How a New Bill Tries to Fix It

Why Rare Disease Clinical Trials Take Too Long and How a New Bill Tries to Fix It

Waiting years for an experimental therapy while driving hours to an academic hospital is a brutal reality for families facing rare conditions. A new bipartisan measure in Congress, the Faster Clinical Trials Act, aims to flip that script by bringing rare disease clinical trials closer to where patients actually live and cutting the red tape that slows down drug testing.

Introduced in late October 2026 by Representatives Jake Auchincloss, a Massachusetts Democrat, and Morgan Griffith, a Virginia Republican, the legislation targets trial costs and patient enrollment times with a clear goal: slice both by at least 30%. If you've ever watched a family scramble to schedule flights, take unpaid time off work, and navigate paperwork just to enroll a sick child or loved one in a study, you know why speed matters. Months of delay aren't abstract policy numbers when a condition is progressive.

Still, passing a bill on Capitol Hill and actually changing how clinical research runs on the ground are two very different things. Let's look at what the legislation proposes, why the current trial model stalls out, and where the real limits lie.

What the Faster Clinical Trials Act Actually Proposes

Most clinical research in the United States is built around a hub-and-spoke setup that forces sick people to travel to specialized centers. Sponsors set up individual trial sites from scratch, recruit participants one study at a time, and rely heavily on in-person visits.

The Faster Clinical Trials Act tries to replace that stop-and-start approach with shared infrastructure. Key elements of the bill include:

  • Reusable clinical trial networks: Instead of rebuilding site agreements, workflows, and screening systems every time a new compound enters testing, the bill pushes for standing networks that can run multiple studies over time.
  • Care closer to home: It expands options to conduct parts of a trial through local doctors' offices, community clinics, or patients' homes rather than requiring constant trips to distant research hospitals.
  • Computer simulations in early stages: The proposal encourages using modeling and simulation earlier in development to sharpen study design and reduce wasted effort before human testing scales up.
  • A dedicated FDA innovation hub and funding: It calls for creating an FDA Center for Clinical Trial Innovation and proposes up to $295 million in agency funding over five years to back modern trial designs and rare disease research.

Lawmakers and policy advisors helping shape the effort point to real-world precedents. Rep. Auchincloss has compared the reusable platform concept to the care and research network built by the Cystic Fibrosis Foundation starting in the 1990s, which helped organize specialized centers and share data across studies. Duke-Margolis Institute for Health Policy founder Mark McClellan, who helped craft the legislation, has emphasized making it far easier for patients to stay put while still participating in rigorous research.

Why Rare Disease Clinical Trials Get Stuck in Neutral

Rare diseases affect small patient populations scattered across huge geographic areas. That math makes traditional trials slow and expensive right out of the gate.

When only a few hundred or a few thousand people in the country have a specific diagnosis, you can't just fill a study at one big city hospital. Sponsors often have to open sites across multiple states, train local staff on unfamiliar endpoints, and wait months to find eligible patients who meet strict inclusion rules. Every week a trial sits open without enough participants drives up overhead and delays answers for families.

Geography hits rural and working-class families hardest. Rep. Griffith has pointed to residents in southwestern Virginia who face two-hour or longer drives just to reach research medical centers—a barrier that applies whether someone is dealing with a chronic lung condition like black lung or an ultra-rare genetic disorder. Add caregiving responsibilities, school schedules, and wage loss into the mix, and promising studies lose eligible volunteers before they even start.

From the regulatory and sponsor side, uncertainty adds another layer of friction. Small populations rarely yield neat, textbook clinical datasets, so drug developers often worry about whether a novel trial design, digital remote measure, or simulated control arm will pass muster with regulators. That caution tends to produce longer timelines and higher costs.

Decentralized Trials Sound Great on Paper. Here Is the Catch.

Shifting more trial activities into homes and local clinics isn't a magic wand. Anyone who has worked around clinical operations or patient advocacy knows decentralized and hybrid trials bring their own headaches.

First, not every therapy can be safely administered at a local clinic or living room. As McClellan has noted, intensive interventions such as certain gene therapies still require specialized academic medical centers. Newer approaches like in vivo gene editing may allow same-day discharge and remote monitoring in some cases, yet safety oversight still depends on tight coordination between local providers and specialty teams.

Second, remote tools create new failure points. Wearables, home phlebotomy, telehealth check-ins, and digital diaries can save a family a grueling drive, but only if devices stay charged, cellular or broadband service holds up, and caregivers aren't drowned in extra tasks. A trial that offloads too much monitoring onto exhausted parents or patients without solid support can backfire through missing data or higher dropout rates.

Third, lawmakers haven't even brought the bill to a floor vote yet. Rep. Griffith has indicated House consideration likely won't happen until next year, while lawmakers have also worked on parallel Senate interest. Even if passed, new FDA centers and multi-year programs take time to staff, write guidance, and change day-to-day industry habits.

How This Fits Alongside Recent FDA Rare Disease Moves

Congress isn't acting in a vacuum. In mid-October 2026, the FDA rolled out its Rare Disease Framework Initiative via a white paper led by the Rare Disease Innovation Hub, aiming for a more "fit-for-purpose" approach to evaluating rare disease drugs and biologics, with public comments running into December.

Put those two tracks together and you see a broader push to modernize how small-population therapies get tested and reviewed. Legislation can authorize funding, build statutory mandates for reusable networks, and push agencies toward modern trial methods. Agency frameworks can clarify review expectations and practical pathways for sponsors. Honestly, both pieces matter—better trial logistics won't move medicines to patients faster if review standards stay murky, and clearer review rules won't fix a broken enrollment pipeline on their own.

What Patients, Caregivers, and Researchers Can Do Right Now

You don't have to wait for a final congressional vote to take practical steps around rare disease research:

  • Ask sponsors about decentralized options early: If you or a loved one are looking into a clinical trial, ask the study coordinator upfront which visits can be done remotely, through telehealth, or at a local lab or physician office, and whether travel or lodging support is covered.
  • Connect with disease-specific advocacy groups: Patient foundations often track active trial networks, registries, and natural history studies far more closely than general search engines, and they frequently help families navigate enrollment hurdles.
  • Track regulatory dockets and legislative updates: Patient advocates and research groups—such as coalitions backing trial modernization—regularly share plain-language updates when bills advance or when the FDA opens public comment periods on rare disease frameworks.
  • Push for practical burden reduction in trial design: If you participate in patient advisory boards or research surveys, flag real-world friction points—like clinic visit frequency, travel distance, and tech setup—so sponsors build trials around human lives rather than convenience.
BF

Bella Flores

Bella Flores has built a reputation for clear, engaging writing that transforms complex subjects into stories readers can connect with and understand.